Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1989 Jun;6(6):501-5.
doi: 10.1023/a:1015924724973.

Short-chain alkyl esters of L-dopa as prodrugs for rectal absorption

Affiliations

Short-chain alkyl esters of L-dopa as prodrugs for rectal absorption

J A Fix et al. Pharm Res. 1989 Jun.

Abstract

The bioavailability of L-dopa following rectal administration of a series of short-chain alkyl esters of L-dopa was determined in rats and dogs. The esters were stable (greater than 360 min) to hydrolysis in physiological buffer. In vitro enzymatic hydrolysis of the esters in plasma was species dependent, with the hydrolytic rate being faster in rat plasma (t 1/2 less than 5 min) than dog plasma (t 1/2 = 68-181 min) or human plasma (t 1/2 = 96-238 min). In vivo hydrolysis in dogs, as indicated by the L-dopa plasma profile following intravenous administration of the esters, was very rapid (high extravascular esterase activity). Significant L-dopa bioavailability was observed in rats following rectal administration of the methyl (46%), ethyl (14%), isopropyl (48%), butyl (100%), and 4-hydroxybutyl (13%) esters of L-dopa (rectal L-dopa absorption, less than 5%). In dogs, significant L-dopa bioavailability was also observed for the methyl (28%), isopropyl (30%), butyl (32%), and 4-hydroxybutyl (34%) esters of L-dopa in the presence of carbidopa. The data indicate that these highly water-soluble (greater than 600 mg/ml) esters of L-dopa are potential candidates for controlled-release rectal delivery systems designed to provide more constant plasma L-dopa levels.

PubMed Disclaimer

References

    1. Lancet. 1982 Aug 21;2(8295):412-5 - PubMed
    1. Neurology. 1975 Feb;25(2):177-83 - PubMed
    1. J Pharm Sci. 1973 Mar;62(3):510-1 - PubMed
    1. Neurology. 1974 Oct;24(10):953-6 - PubMed
    1. J Neurol Neurosurg Psychiatry. 1975 Feb;38(2):129-35 - PubMed

LinkOut - more resources